

2024

ESH MASTER Plan

For Hypertension Management




Professor Ye Myint
President

Myanmar Society of Hypertension (MMSH)
Senior Medical Superintendent
Nay Pyi Taw General hospital (1000bedded)



Towards Holistic &
Comprehensive Cardiac Care

1.28 billion people live with Hypertension worldwide



Prevalence of Hypertension by world region

- 46% of adults with hypertension are unaware
- 42% with hypertension are diagnosed and treated.
- Approximately 1 in 5 adults with hypertension have it under control.
- In Myanmar, the prevalence of hypertension was 30.1% in males and 29.8% in females.

ESH MASTERplan for Hypertension Management



Towards Holistic &
Comprehensive Cardiac Care



© ESH 2024

ESH MASTERplan for Hypertension Management



Towards Holistic & Comprehensive Cardiac Care



- **CORNERSTONE** for the diagnosis and management of hypertension.
- **FIRST PIVOTAL STEP** of the ESH MASTERplan for the management of hypertension.

© ESH 2024

Office BP measurement (OBPM)



24-hour BP monitoring (ABPM)

Home BP monitoring



**Always based
on the average of
several
measurements**

Daytime (awake):
SBP ≥ 135 mmHg
and/or
DBP ≥ 85

*Nighttime (asleep):
SBP ≥ 120 mmHg
and/or
DBP ≥ 70

Office BP measurement (OBPM)



*SBP ≥ 140
and/or
DBP ≥ 90

Conditions

1. Validated automated electronic upper-arm cuff device (www.stridebp.org).
2. Appropriate cuff to fit arm size.
3. Quiet room – comfortable temperature.
4. No smoking, caffeine, food, exercise (30').
5. 3-5' seated and relaxed.
6. No talking during/ between measurements.

METHODOLOGY



Relevance

- Used in **outcome trials**.
- Basis for **diagnosis - BP targets**.

Posture

7. Sitting - back supported on chair.
8. Legs un-crossed, feet flat on floor.
9. Bare arm resting on table – mid-arm at heart level.

Measurement

10. Take 3 readings at 1' intervals. Use average of last 2.

Home BP monitoring (HBPM)



*SBP ≥ 135
and/or
DBP ≥ 85

Conditions/Posture: As Office BP Measurement

Protocol

- Educate patient: validated device - report data.
- Standardized Protocol:
- 3-7 days before office visits.
- Morning and evening (before drug intake if treated).
- 2 readings – 1' min interval.
- Average all readings – Exclude 1st day.


Relevance

- Recommended for **long-term follow-up** of treated HTN.
- **Improves BP control**, especially when combined with education/counselling.
- Confirm HTN diagnosis - true resistant HTN – particularly if ABPM not available.

Long-term follow-up (*treated HTN*)

- Duplicate measurements.
- Once or twice per week, or per month.

Ambulatory BP monitoring (ABPM)



*24-h mean BP:



SBP ≥ 130
and/or
DBP ≥ 80

*Daytime (awake):



SBP ≥ 135 mmHg
and/or
DBP ≥ 85

*Nighttime (asleep):



SBP ≥ 120 mmHg
and/or
DBP ≥ 70

METHODOLOGY

Towards Holistic &
Comprehensive Cardiac Care

Relevance

- Obtain **24h BP profile** including night (sleep) not captured by OBPM or HBPM.
- Confirm **HTN diagnosis** - true resistant HTN.

Validated device and cuff: As for Office BP.

Protocol

- Routine workday for 24h.
- 20' intervals day (awake) and night (sleep).
- Diary: sleep times, drug intake times, symptoms, activities, unusual problems.

Home/Ambulatory BP Monitoring - Indications



When White-Coat HTN is common

- Grade I hypertension
- High office BP without HMOD

When Masked HTN is common

- High-normal office BP
- Normal office BP with HMOD or high CV risk

In treated individuals

- Confirmation of uncontrolled/resistant HTN
- Evaluation of 24h BP control (especially high-risk)
- Symptoms of hypotension (especially older)

Other Conditions

- Suspected postural or postprandial hypotension (treated)
- Exaggerated BP response to exercise
- Considerable office BP variability

Specific Indications

ABPM

- Nocturnal BP, dipping (OSA, CKD, DM, endocrine HTN, autonomic dysfunction)
- Patients incapable or unwilling to perform HBPM, or anxious
- Considering renal denervation
- Children – Pregnancy

HBPM

- Long-term follow-up (adherence – BP control)
- Patients unwilling to perform ABPM


Repeat

- Confirm White-Coat and Masked HTN (untreated or treated)

ESH MASTERplan for Hypertension Management



European
Society of
Hypertension^{re}



- Emphasis on “accurate” BP measurement.
- Validated electronic upper arm-cuff BP monitors.
- Measurement protocols.

Office BP →

Basis for HTN evaluation.

Home BP →

For most treated individuals.


24h ABP →

Unique diagnostic method.

ESH MASTERplan for Hypertension Management



Towards Holistic &
Comprehensive Cardiac Care



© ESH 2024

Assess patient



**Assessment of patients should be adapted
according to the severity of hypertension
and clinical circumstances.**

Assess patient



Basic evaluation: Medical history

- Personal Hypertension related aspects, Family history; Risk factors and Comorbidities

Personal history

- Time of the first diagnosis of hypertension, including records of any previous medical screening, hospitalization
- Stable or rapidly increasing BP
- Recordings of current and past BP values by self BP measurements
- Current/past antihypertensive medications including their effectiveness and intolerance
- Adherence to therapy
- Previous hypertension in pregnancy/preeclampsia

Assess patient



Basic evaluation: Medical history

- Cardiovascular risk factors
- Symptoms of HMOD, CVD, stroke or CKD
- Other drug treatments or use including over the counter (OTC)



Drug treatments or use (other than antihypertensive drugs)

- Recreational drug/substance abuse, concurrent therapies including nonprescription drugs, e.g. glucocorticoids, NSAIDs/COX-2 inhibitors, paracetamol (acetaminophen), immunosuppressive drugs, anticancer drugs, nasal vasoconstrictors

Assess patient



Basic evaluation: Medical history

- Possible secondary hypertension


History of possible secondary hypertension

- Young onset of grade 2 or 3 hypertension (<40 years), or sudden development of hypertension or rapidly worsening BP in older patients
- History of repetitive renal/urinary tract disease
- Repetitive episodes of sweating, headache, anxiety or palpitations, suggestive of pheochromocytoma
- History of spontaneous or diuretic-provoked hypokalemia, episodes of muscle weakness and tetany (hyperaldosteronism)
- Symptoms suggestive of thyroid disease or hyperparathyroidism
- History of or current pregnancy, postmenopausal status and oral contraceptive use or hormonal substitution

Assess patient

Basic evaluation: Medical history

- Possible secondary Hypertension depending on age of onset



Assess patient

Basic evaluation: Physical Examination

- ✓ Weight and height with calculation of BMI
 - ✓ Body build and posture
 - ✓ Waist circumference
-
- ✓ Skin inspection
 - ✓ Auscultation of heart and carotid arteries
 - ✓ Neurological examination and cognitive status
 - ✓ Resting pulse rate
 - ✓ Signs of HMOD




Assess patient

Basic evaluation: Physical Examination Older Patient

- Level of frailty/functionality in older persons > 80 years



Basic evaluation: Physical Examination Older Patient

- Level of frailty/functionality in older persons > 80 years
 - Assess functional status as a measurement to perform activities of daily living independently. The Index ranks adequacy of performance in the six functions:
 - ✓ bathing,
 - ✓ dressing,
 - ✓ toileting,
 - ✓ transferring,
 - ✓ continence,
 - ✓ feeding.
- 
- 5, 6 full function= Group 1
3, 4 moderate= Group 2
1,2 impairment = Group 3

Assess patient

Basic evaluation : Investigation with lab test and other

Lab test: blood serum / plasma

- Hemoglobin and/or hematocrit
- Fasting blood glucose and HbA1c
- Blood lipids: Total COL, LDL, HDL, triglycerides
- Blood potassium and sodium
- Uric acid
- Serum creatinine with calculation of eGFR
- Blood calcium

Urine:

- Urinary albumin/creatinine ratio
- Urine analysis (multicomponent dipstick test; first voided urine in the morning)

Other investigation:

- ECG




Assess patient



Basic evaluation: Investigation with lab test and other

What if I need to assess more information?



Extended Assessment

Assess patient




HMOD: Select if deemed necessary and available

History and symptoms of HMOD, CVD, stroke and kidney disease

- Brain and eyes: headache, vertigo, syncope, impaired vision, TIA, sensory or motor deficit, stroke, carotid revascularization, cognitive impairment, memory loss, dementia (in older people)
- Heart: chest pain, shortness of breath, edema, myocardial infarction, coronary revascularization, syncope, history of palpitations, arrhythmias (especially AF), heart failure
- Kidney: thirst, polyuria, nocturia, hematuria, urinary tract infections
- Peripheral arteries: cold extremities, intermittent claudication, pain-free walking distance, pain at rest, ulcer or necrosis, peripheral revascularization
- Patient or family history of CKD (e.g. polycystic kidney disease)

Assess patient → Extended Assessment

HMOD: Select if deemed necessary and available



Echocardiography

MRI

Coronary Calcium score



Convent. US

Doppler US



Carotid ultrasound





Pulse wave velocity

Ankle-brachial index



Cognitive funtion tests

Brain imaging




Fundoscopy

Retinal micro- vasculature


Assess patient

Basic and extended evaluation

What if I need to assess more information, investigation or other care




Refer to a specialist or to the hospital



Assess patient

When to refer a patient: To a hospital


- Hypertensive emergencies, i.e. in severe hypertension (grade 3) associated with acute symptomatic HMOD
- Severe hypertension with conditions that need intensified BP management:
 - Acute stroke
 - Complicated aortic aneurysm
 - Acute heart failure
 - Acute coronary syndrome
 - Acute kidney failure
- Hypertension caused by pheochromocytoma or exogenous sympathomimetic substances (e.g. substance abuse)
- Severe forms of Hypertension during Pregnancy including preeclampsia/eclampsia



Assess patient



**Patient's personal and medical history, other relevant factors
and co-morbidities
that may impact their blood pressure, CV risk and management.**




**Physical examination,
basic lab tests and 12 leads ECG**

ESH MASTERplan for Hypertension Management



Towards Holistic &
Comprehensive Cardiac Care



© ESH 2024

The selection of the best individual therapy is based on the level of **Cardiovascular risk**


Towards Holistic & Comprehensive Cardiac Care

Hypertension disease staging	Other risk factors, HMOD, CVD or CKD	BP (mmHg) grading			
		High-normal SBP 130–139 DBP 85–89	Grade 1 SBP 140–159 DBP 90–99	Grade 2 SBP 160–179 DBP 100–109	Grade 3 SBP ≥ 180 DBP ≥ 110
Stage 1	No other risk factors	Low risk	Low risk	Moderate risk	High risk
	1 or 2 risk factors	Low risk	Moderate risk	Moderate to high risk	High risk
	≥3 risk factors	Low to moderate risk	Moderate to high risk	High risk	High risk
Stage 2	HMOD, CKD grade 3, or diabetes mellitus	Moderate to high risk	High risk	High risk	Very high risk
Stage 3	Established CVD or CKD grade ≥4	Very high risk	Very high risk	Very high risk	Very high risk


<50 years	50–69 years	≥70 years
<2.5%	<5%	<7.5%
2.5 to <7.5%	5 to <10%	7.5 to <15%
≥7.5%	≥10%	≥15%

Complementary risk estimation in Stage 1 with SCORE2/SCORE2-OP


Select Therapy: Initial management according to the level of risk




Select Therapy: Initial management according to the level of risk












Select Therapy: Initial management according to the level of risk



Select Therapy: Lifestyle interventions



Towards Holistic &
Comprehensive Cardiac Care

Relevance	Prescribing	Supportive additional interventions
<ul style="list-style-type: none"> Prevent or delay onset of hypertension Improve overall/CV health and well-being Reduce BP Booster BP lowering effects of medications Reduce the number/dose of drugs needed for BP control 	<ul style="list-style-type: none"> To all patients with diagnosed hypertension To patients with white-coat or masked hypertension To patients with high-normal BP Individual patient counseling and support Prescribe with specific instructions, e.g. intensity and type of exercise Assess, adapt, and reinforce during follow-up 	<p>Smoking cessation</p> <ul style="list-style-type: none"> Smoking cessation, supportive care and referral to smoking cessation programs are recommended for all smokers 
Key interventions to reduce BP		
<p>Healthy diet</p> <p>Prefer:</p> <ul style="list-style-type: none"> DASH or Mediterranean type diets A healthy dietary pattern including more plant-based and less animal-based food Vegetables, fruits, beans, nuts, seeds, and vegetable oils Lean protein (e.g. fish, poultry)  <p>Limit:</p> <ul style="list-style-type: none"> Fatty meats, full-fat dairy Sugar, sweets and sweetened beverages <p>Daily physical activity and regular exercise</p> <ul style="list-style-type: none"> Incorporate physical activity (e.g. walking, cycling) into everyday life and reduce sedentary behavior (e.g. sit less) Aim for: <ul style="list-style-type: none"> -150-300 min of aerobic exercise per week performed at a moderate intensity or -75-150 min of aerobic exercise per week performed at a vigorous intensity or -an equivalent combination of moderate and vigorous physical activities Add dynamic resistance (muscle strengthening) exercise 2-3 times per week Start slow and gradually to build up the amount/intensity of activity 	<p>Weight reduction</p> <ul style="list-style-type: none"> Combine a low-caloric diet with daily physical activity in patients with overweight or obesity Monitor waist circumference and weight  <p>Restriction of sodium intake</p> <ul style="list-style-type: none"> Sodium is mainly consumed as salt, which comes from processed foods or is added to the food during cooking or at the table Salt (NaCl) restriction to < 5 g (~2g sodium) or 1 teaspoon per day is recommended  <p>Augmentation of potassium intake</p> <ul style="list-style-type: none"> Increase potassium consumption, preferably via dietary modification, except for hypertensive patients with advanced CKD Foods high in potassium are for example white cannellini beans (1200 mg/cup), unsalted boiled spinach (840 mg/cup), avocado (708 mg/cup) and bananas (450 mg per medium fruit) Use salt substitutes replacing NaCl with KCl in patients consuming a high sodium diet  <p>Limit alcohol intake</p> <ul style="list-style-type: none"> Limit alcohol intake close to abstinence, particularly if intake is ≥ 3 drinks/day^a Avoid excessive (binge) drinking 	<p>Improve stress management</p> <ul style="list-style-type: none"> Reduce stress by use of <ul style="list-style-type: none"> -Regular physical activity -Mindfulness-based exercise -Relaxation techniques, e.g. deep breathing, meditation, yoga or Tai Chi Get enough sleep (7-9 hours) Find individual ways to cope with stress, e.g. practicing mindfulness, engaging in hobbies or talking to a therapist Moderate alcohol and caffeine intake, avoid drugs  <p>Minimize exposure to noise and air pollution</p> <ul style="list-style-type: none"> Reduce indoor exposure to noise and air pollution. Consider to reduce exposure to air pollution by modifying the location, timing and type of outdoor activities 


^aAbout 350 ml of regular beer containing 5% alcohol by volume or 150 ml of wine containing 12% alcohol by volume per drink.

© ESH 2024

Select Therapy: Drug Therapy and Target BP




Towards Holistic & Comprehensive Cardiac Care



Select Therapy: Drug Therapy and Target BP






Towards Holistic & Comprehensive Cardiac Care



Select Therapy: Drug Therapy and Target BP in Older Patients




	Fit* 	Slowed but autonomous for most activities* 	Severely Dependent 
Treatment initiation	<ol style="list-style-type: none"> 1. If office SBP ≥ 160 mmHg. 2. Consider also in most cases if office SBP is between 140 and 159 mmHg. 	<ol style="list-style-type: none"> 1. If office SBP ≥ 160 mmHg. 2. Consider also in most cases if office SBP is between 140 and 159 mmHg. 	<ol style="list-style-type: none"> 1. According to comorbidities and polypharmacy. 2. Consider treatment if office SBP ≥ 160 mmHg.
Target BP	<ol style="list-style-type: none"> 3. Office SBP in the range of 140 to 150 mmHg. 4. A range of 130-139 mmHg may be considered if well tolerated 5. Be cautious if DBP is already below 70 mmHg. 	<p>3-5 from Fit apply also.</p>	<ol style="list-style-type: none"> 3. Office SBP in the range of 140 to 150 mmHg.
Strategy	<ol style="list-style-type: none"> 6. Consider starting with monotherapy. <p>^aSee Table 5: How to Assess</p>	<ol style="list-style-type: none"> 6. Consider starting with monotherapy. 7. Uptitrate cautiously. 8. Reduce treatment if SBP is very low (<120 mmHg) or in patients with orthostatic hypotension. 9. Consider a detailed assessment of functional status with the tools below or equivalent:: <ul style="list-style-type: none"> • Mobility (Short Physical Performance Battery) • Muscular force (Handgrip) • Depression (Mini Geriatric Depression Scale) • Nutrition (Mini Nutritional Assessment Short Form) 	<ol style="list-style-type: none"> 4. Start treatment cautiously. 5. Reduce treatment if SBP is very low (<120 mmHg) or in patients with orthostatic hypotension. 6. Correct other factors and medications lowering BP.

© ESH 2024

ESH MASTERplan for Hypertension Management



Towards Holistic &
Comprehensive Cardiac Care



© ESH 2024


Evaluate Response

Below 140/80 mm ASAP and more

Towards Holistic &
Comprehensive Cardiac Care



General office BP targets in patients with hypertension



Evaluate Response



Initiation 0- 3 months

Aim for BP control ASAP.

- 1-2 visits (4-6 weeks)
- Office BP and Home BP
- Support individual (shared decision making); Verify initiation and discuss adherence. Verify and adapt lifestyle interventions and recommend drug therapy prescribing patterns
- Selected lab tests to address safety of drug therapy / risk factors
- Re-Assess modifiable risk factors and HMOD

Evaluate Response



Short term Follow Up 3-12 months



Optimise BP control ASAP.

- 1-2 visits depending on CV risk and difficulty to control BP (4-6 weeks)
- Office BP and Home BP (before visits)
- ABPM in apparent treatment resistance hypertension(refer to a specialist)
- Periodic re-assessment of parameters with impact on drug safety and selection, e.g. eGFR, potassium ,risk factors, e.g. glucose, HbA1c, LDL- cholesterol
- Verify BP- induced changes on HMOD (eGFR, albuminuria, PWV or LVH)

Evaluate Response



Short term Follow Up 3-12 months

Build an effective ecosystem

- Support implementation of lifestyle interventions. Consider adjustment of medications depending on BP control, tolerability and change in co- morbidities, avoid inertia. Consider deprescribing in symptomatic very old and frail patients with low BP.
- Monitor adherence/persistence to drug therapy: assess barriers, e.g. changes in co-morbidities, side-effects, polypharmacy including OTC use
- Organize and implement patient support: consider use of team-based care, telehealth, virtual visits, self-monitoring and patient empowerment

Evaluate Response



Long term Follow Up > 12 months



Maintain optimal BP control

- Low-risk : 1 visit per year
- High risk and difficult to control BP: more frequent visits (2-3/year)
- In patients without pre-existing HMOD re-assess in longer intervals, e.g. every 3 years
- In patients with pre-existing HMOD more frequent re-assessments of BP- induced changes
- Maintain patient support

ESH MASTERplan for Hypertension Management



Towards Holistic &
Comprehensive Cardiac Care



© ESH 2024



Thank you

References

- 1. Bjertness MB, Htet AS, Meyer HE, Htike MMT, Zaw KK, Oo WM, et al. Prevalence and determinants of hypertension in Myanmar - a nationwide cross-sectional study. BMC Public Health. 2016 Dec;16(1):590.
- 2. Noncommunicable and Health Promotion Unit The WHO. Indicator Metadata Registry Details [Internet]. [cited 2023 May 10]. Available from: <https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3155>
- 3. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334–57.
- 4. Than Lwin Tun, Kyaw Kan Kaung, Nan Nai Nai Shein. Community health clinics combat hypertension, diabetes in rural areas once a week across the nation [Internet]. MDN - Myanmar DigitalNews. [cited 2023 May 11]. Available from: <https://www.mdn.gov.mm/en/community-health-clinics-combat-hypertension-diabetes-rural-areas-once-week-across-nation>

